Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting
– BT7480 has been selected as the Company’s lead immuno-oncology candidate to advance into IND-enabling studies CAMBRIDGE, England & BOSTON–(BUSINESS…